On July 16, Abbott Laboratories rose 6.42% in regular trading, trading at $95.355/share, with turnover of $69.94 million. The rally was driven by the company's stronger-than-expected second-quarter results and an upward revision to full-year earnings guidance.

Abbott reported Q2 revenue of $12.593 billion, up 13.0% year-over-year from $11.14 billion, beating the FactSet consensus estimate of $12.497 billion. Adjusted earnings per share came in at $1.31, exceeding the $1.28 estimate. The company raised its full-year adjusted EPS guidance to $5.45–$5.60 from the prior range of $5.38–$5.58, while reaffirming comparable sales growth of 6.5%–7.5%. For Q3, Abbott projected adjusted EPS of $1.38–$1.46 versus the $1.42 consensus.

Notably, Abbott had previously lowered its annual guidance following Q1 results due to soft diabetes product sales and short-term financial pressure from its approximately $21 billion acquisition of Exact Sciences, which had weighed on shares since April. The Q2 beat signals accelerating growth momentum in the second half.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)